Total Payments
$836.54
2023 Payments
$99.99
Companies
11
Transactions
12
Medicare Patients
22,409
Medicare Billing
$5.9M
Payment Breakdown by Category
Food & Beverage$588.10 (70.3%)
Education$217.19 (26.0%)
Other$31.25 (3.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $588.10 | 7 | 70.3% |
| Education | $217.19 | 4 | 26.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $31.25 | 1 | 3.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $131.90 | 1 | $0 (2018) |
| Merck Sharp & Dohme Corporation | $123.84 | 1 | $0 (2019) |
| Seagen Inc. | $115.56 | 2 | $0 (2023) |
| Allergan Inc. | $107.40 | 1 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $100.55 | 1 | $0 (2019) |
| Incyte Corporation | $92.99 | 1 | $0 (2018) |
| Eisai Inc. | $86.92 | 1 | $0 (2017) |
| PFIZER INC. | $31.25 | 1 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $21.92 | 1 | $0 (2019) |
| Seattle Genetics, Inc. | $12.29 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $99.99 | 1 | Seagen Inc. ($99.99) |
| 2022 | $15.57 | 1 | Seagen Inc. ($15.57) |
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2019 | $353.71 | 4 | Merck Sharp & Dohme Corporation ($123.84) |
| 2018 | $268.43 | 4 | Genentech USA, Inc. ($131.90) |
| 2017 | $86.92 | 1 | Eisai Inc. ($86.92) |
All Payment Transactions
12 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/26/2023 | Seagen Inc. | — | Education | In-kind items and services | $99.99 | General |
| 05/13/2022 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $15.57 | General |
| Category: Oncology | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 10/15/2019 | Allergan Inc. | NATRELLE (Device) | Food and Beverage | In-kind items and services | $107.40 | General |
| Category: PLASTICS | ||||||
| 05/29/2019 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $100.55 | General |
| 05/22/2019 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $123.84 | General |
| 05/06/2019 | AstraZeneca Pharmaceuticals LP | FASLODEX (Drug) | Food and Beverage | In-kind items and services | $21.92 | General |
| Category: Oncology | ||||||
| 08/01/2018 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $12.29 | General |
| Category: Oncology | ||||||
| 07/25/2018 | Genentech USA, Inc. | Perjeta (Biological) | Food and Beverage | In-kind items and services | $131.90 | General |
| Category: BioOncology | ||||||
| 06/30/2018 | PFIZER INC. | BOSULIF (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $31.25 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 03/16/2018 | Incyte Corporation | — | Education | Cash or cash equivalent | $92.99 | General |
| 03/15/2017 | Eisai Inc. | Halaven (Drug) | Food and Beverage | Cash or cash equivalent | $86.92 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 59 | 4,934 | 52,028 | $4.3M | $863,351 |
| 2022 | 65 | 5,212 | 69,181 | $5.3M | $1.2M |
| 2021 | 78 | 6,294 | 144,335 | $9.0M | $2.1M |
| 2020 | 71 | 5,969 | 146,866 | $7.8M | $1.8M |
Total Patients
22,409
Total Services
412,410
Medicare Billing
$5.9M
Procedure Codes
273
All Medicare Procedures & Services
273 procedure records from CMS Medicare Utilization — Page 1 of 11
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 23 | 10,800 | $1.6M | $467,382 | 29.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 361 | 611 | $110,316 | $39,369 | 35.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 11 | 2,040 | $145,620 | $38,147 | 26.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 212 | 395 | $119,227 | $36,865 | 30.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 90 | 334 | $278,713 | $33,726 | 12.1% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 24 | 13,010 | $273,210 | $30,842 | 11.3% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 50 | 1,341 | $234,675 | $23,874 | 10.2% |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Office | 2023 | 13 | 276 | $242,604 | $23,361 | 9.6% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 11 | 288 | $415,872 | $21,896 | 5.3% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 415 | 1,352 | $83,824 | $13,965 | 16.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 427 | 1,621 | $56,735 | $12,308 | 21.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 401 | 1,372 | $26,068 | $11,500 | 44.1% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 26 | 140 | $34,882 | $7,804 | 22.4% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 235 | 445 | $25,810 | $5,908 | 22.9% |
| 82607 | Cyanocobalamin (vitamin b-12) level | Office | 2023 | 214 | 360 | $26,640 | $5,280 | 19.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 22 | 106 | $43,155 | $5,211 | 12.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 49 | 431 | $45,255 | $5,140 | 11.4% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 116 | 145 | $14,790 | $4,392 | 29.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 26 | 26 | $15,081 | $4,366 | 29.0% |
| 82746 | Folic acid level, serum | Office | 2023 | 192 | 300 | $21,300 | $4,283 | 20.1% |
| J1750 | Injection, iron dextran, 50 mg | Office | 2023 | 16 | 320 | $24,925 | $4,267 | 17.1% |
| 83520 | Measurement of substance using immunoassay technique | Office | 2023 | 48 | 252 | $45,612 | $4,265 | 9.4% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 61 | 456 | $24,624 | $4,156 | 16.9% |
| 83550 | Iron binding capacity | Office | 2023 | 234 | 442 | $15,028 | $3,764 | 25.0% |
| 86334 | Immunologic analysis technique on serum (immunofixation) | Office | 2023 | 69 | 152 | $23,560 | $3,327 | 14.1% |
About Dr. Gauri Radkar, D.O
Dr. Gauri Radkar, D.O is a Hematology & Oncology healthcare provider based in Virginia Beach, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/22/2005. The National Provider Identifier (NPI) number assigned to this provider is 1457338204.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gauri Radkar, D.O has received a total of $836.54 in payments from pharmaceutical and medical device companies, with $99.99 received in 2023. These payments were reported across 12 transactions from 11 companies. The most common payment nature is "Food and Beverage" ($588.10).
As a Medicare-enrolled provider, Radkar has provided services to 22,409 Medicare beneficiaries, totaling 412,410 services with total Medicare billing of $5.9M. Data is available for 4 years (2020–2023), covering 273 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Virginia Beach, VA
- Active Since 12/22/2005
- Last Updated 04/14/2011
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1457338204
Products in Payments
- Perjeta (Biological) $131.90
- NATRELLE (Device) $107.40
- Halaven (Drug) $86.92
- BOSULIF (Drug) $31.25
- FASLODEX (Drug) $21.92
- TUKYSA (Drug) $15.57
- ADCETRIS (Biological) $12.29
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Virginia Beach
Yue Zhang, Md, MD
Hematology & Oncology — Payments: $81,368
Hematology & Oncology $81,368
Celesteann Bremer, M.d, M.D
Hematology & Oncology — Payments: $5,776
Hematology & Oncology $5,776
Dr. Bhaskar Rao, Md, MD
Hematology & Oncology — Payments: $325.56
Hematology & Oncology $325.56
Dr. Carolina Longa, Md, MD
Hematology & Oncology
Hematology & Oncology